Are you over 18 and want to see adult content?
More Annotations
A complete backup of lemacaron-us.com
Are you over 18 and want to see adult content?
A complete backup of teachyourmonstertoread.com
Are you over 18 and want to see adult content?
A complete backup of galatiinternational.com
Are you over 18 and want to see adult content?
A complete backup of bestglobalbrands.com
Are you over 18 and want to see adult content?
A complete backup of ncelectriccooperatives.com
Are you over 18 and want to see adult content?
A complete backup of bluebirdbotanicals.com
Are you over 18 and want to see adult content?
A complete backup of motordesktop.com
Are you over 18 and want to see adult content?
A complete backup of svadbavsibiri.ru
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of amateurvoyeurforum.com
Are you over 18 and want to see adult content?
A complete backup of badgirlsblog.com
Are you over 18 and want to see adult content?
A complete backup of www.naijauncut.com
Are you over 18 and want to see adult content?
A complete backup of grometsplaza.net
Are you over 18 and want to see adult content?
A complete backup of www.asiaerotica.com
Are you over 18 and want to see adult content?
A complete backup of brutal-facesitting.com
Are you over 18 and want to see adult content?
Text
CANCER WORLD
Cancer World explores cancer care from all viewpoints publishing online articles and news weekly and a print version twice a year. CANCER CAUSED BY OCCUPATIONAL EXPOSURE NEEDS URGENT What is the cancer burden associated with occupational exposure? A new review shows that the question needs urgent attention, given under-reporting and current difficulties in estimating the global burden. The review, in Molecular Oncology, highlights how millions of workers are exposed daily to crystalline silica in mineral dust, diesel engine exhaust emissions, welding fumes and GORDON MCVIE 1945–2021: A LIFETIME DEDICATED TO DEFEATING Gordon McVie passed away on January 20th after a lifetime of pioneering contributions to the cause of defeating cancer: as clinician, researcher, manager, advocate and educator. He was a formidable presence on the UK and European stage, driven by a conviction that science can and will defeat cancer; quick to spot and embrace new opportunities; RARE CANCER CARE: ARE EUROPEAN REFERENCE NETWORKS What value can collaboration between EU member states add to the quality of care accessible to all EU citizens? It’s a question that has become urgent and topical with the coronavirus pandemic, and one that EU4Health, the EU’s new funding programme “for a healthier and safer Union”, presented at the end of May, seeks to address.Part of the programme involves expanding existing DOSE DENSE CHEMOTHERAPY IN LUMINAL B BREAST CANCERS Interview with Lucia Del Mastro, MD, Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genova, Italy. Q. Your recent paper in the European Journal of Cancer (EJC 136 (2020) 43-51) on the GIM2 trial is clearly the result of a considerable effort at national level, with many contributing centresall over
WHEN PATIENTS ASK YOU TO HELP THEM DIE NUTRITIONAL SUPPORT FOR CANCER PATIENTS Patients who are receiving adequate nutrition have a better prognosis, respond better to chemotherapy and can tolerate higher doses of anticancer treatments. It is therefore important for oncologists to assess and manage malnutrition. Malnutrition, which is easily identified during clinical examination by weight loss and hypophagia, is an independent negative prognostic factor for cancer WHEN YOUR TIME IS UP. CONVERSATIONS ABOUT DYING FROM Cancer has traditionally been the diagnosis people fear most. But is dying from cancer so much worse than the alternatives? Anna Wagstaff tries to make sense of an emotive discussion that all started with a post on the BMJ blog. “How do you want to die? You must think aboutit.” This is
HOW DOCTORS DIE. IT’S NOT LIKE THE REST OF US, BUT IT This hard-hitting blogpost by Ken Murray, a retired Los Angeles family doctor, helped open up discussions about why doctors routinely administer treatments to dying patients that they would adamantly refuse for themselves. Years ago, Charlie, a highly respected orthopaedist and a mentor of mine, found a lump in his stomach. He hada surgeon explore
MANAGING COMMON TOXICITIES WITH NEW TYROSINE KINASESEE MORE ON ARCHIVE.CANCERWORLD.NETCANCER WORLD
Cancer World explores cancer care from all viewpoints publishing online articles and news weekly and a print version twice a year. CANCER CAUSED BY OCCUPATIONAL EXPOSURE NEEDS URGENT What is the cancer burden associated with occupational exposure? A new review shows that the question needs urgent attention, given under-reporting and current difficulties in estimating the global burden. The review, in Molecular Oncology, highlights how millions of workers are exposed daily to crystalline silica in mineral dust, diesel engine exhaust emissions, welding fumes and GORDON MCVIE 1945–2021: A LIFETIME DEDICATED TO DEFEATING Gordon McVie passed away on January 20th after a lifetime of pioneering contributions to the cause of defeating cancer: as clinician, researcher, manager, advocate and educator. He was a formidable presence on the UK and European stage, driven by a conviction that science can and will defeat cancer; quick to spot and embrace new opportunities; RARE CANCER CARE: ARE EUROPEAN REFERENCE NETWORKS What value can collaboration between EU member states add to the quality of care accessible to all EU citizens? It’s a question that has become urgent and topical with the coronavirus pandemic, and one that EU4Health, the EU’s new funding programme “for a healthier and safer Union”, presented at the end of May, seeks to address.Part of the programme involves expanding existing DOSE DENSE CHEMOTHERAPY IN LUMINAL B BREAST CANCERS Interview with Lucia Del Mastro, MD, Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genova, Italy. Q. Your recent paper in the European Journal of Cancer (EJC 136 (2020) 43-51) on the GIM2 trial is clearly the result of a considerable effort at national level, with many contributing centresall over
WHEN PATIENTS ASK YOU TO HELP THEM DIE NUTRITIONAL SUPPORT FOR CANCER PATIENTS Patients who are receiving adequate nutrition have a better prognosis, respond better to chemotherapy and can tolerate higher doses of anticancer treatments. It is therefore important for oncologists to assess and manage malnutrition. Malnutrition, which is easily identified during clinical examination by weight loss and hypophagia, is an independent negative prognostic factor for cancer WHEN YOUR TIME IS UP. CONVERSATIONS ABOUT DYING FROM Cancer has traditionally been the diagnosis people fear most. But is dying from cancer so much worse than the alternatives? Anna Wagstaff tries to make sense of an emotive discussion that all started with a post on the BMJ blog. “How do you want to die? You must think aboutit.” This is
HOW DOCTORS DIE. IT’S NOT LIKE THE REST OF US, BUT IT This hard-hitting blogpost by Ken Murray, a retired Los Angeles family doctor, helped open up discussions about why doctors routinely administer treatments to dying patients that they would adamantly refuse for themselves. Years ago, Charlie, a highly respected orthopaedist and a mentor of mine, found a lump in his stomach. He hada surgeon explore
MANAGING COMMON TOXICITIES WITH NEW TYROSINE KINASESEE MORE ON ARCHIVE.CANCERWORLD.NETCANCER WORLD
Cancer World explores cancer care from all viewpoints publishing online articles and news weekly and a print version twice a year. WWW.CANCERWORLD.NET ISSUE 90 SUMMER 2021 Scan to access haping the future of cancer care our website Readership of over 000 ‘Covid did not stop cancer research’ by Vito Manolo Roma Editor-in-chief Adriana Albini Senior Associate Editor HIGHLIGHTS OF 2020 AMERICAN SOCIETY OF HEMATOLOGY (ASH Like most 2020 meetings the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held 5-8 December, was hosted virtually. Due to meticulous planning, the format did not prevent delegates attending the largest gathering of the professional haematology community from undergoing the full conference experience. There was a wide ranging and innovative scientific CONTAGION: A NARRATIVE APPROACH TO UNDERSTANDING THE The coronavirus pandemic, as experienced in the lives of individuals and by society, is so much more than a biological phenomenon. We need to grasp this to effectively address the continuing damage it is doingas we move forward.
HIGHLIGHTS OF 2020 SAN ANTONIO BREAST CANCER SYMPOSIUM In 2020, the San Antonio Breast Cancer Symposium (SABCS) co-organised in association with the American Association for Cancer Research (AACR) celebrated its 43rd year as the world’s premier annual breast oncology meeting. Like most conferences, due to the Covid-19 pandemic, for the first time this meeting was hosted as a virtual event. THE COST OF CANCER IN EUROPE Thomas Hofmarcher is a health economist with a strong focus on policy-relevant analysis. He is an expert of cost-of-illness analysis, patient access studies, cost-effectiveness analysis, budget impact analysis, market forecast models to the application of advanced econometric methods in both Swedish and European contexts. GUT MICROBIOME POSITIVELY INFLUENCES ABIRATERONE RESPONSE Abiraterone acetate (AA), an agent used in castrate-resistant prostate cancer, promotes a shift towards health-associated, anti-inflammatory gut commensal bacteria, finds a study in Nature Communications. “These findings clearly demonstrate that the gut microbiome is playing a role in treatment response,” says Jeremy Burton, the study lead investigator from the University of Western EASING THE CANCER JOURNEY Having to travel long distances or stay away from home while being treated for cancer takes its toll in anxiety, stress and isolation. Could more be done to ensure policies that centralise services don t make some patients lives unbearable? Since his diagnosis in 2009, Dearn McClintock has been undergoing tests and treatment for prostatecancer
RECOGNISING AND REDUCING THE RISK OF CHEMOTHERAPY When chemotherapy drugs leak from the veins it can cause serious injury to the patient, greatly heighten their fears of undergoing future treatment cycles, and undermine their trust in their medical team. Knowing how to assess and reduce the risks, and what to do when things go wrong, is essential. Extravasation occurs when medicinesleak
IS THIS THE END FOR THE MICROSCOPE? New generations of precision digital scanners are threatening to replace the tool that has been the iconic symbol of pathology for so long. Maria Delaney reports. Glass slides containing tissues and cells are sitting in piles on a shelf in the pathology lab. They wait here until the consultant picks up a stack and carriesCANCER WORLD
Cancer Nurses – The Key To Prevention, Risk Reduction And Tackling The European Cancer Burden. External Contributor. 11 May 2021. European Cancer Nursing Day (ECND21), takes place every year on 18 May, organised by the European Oncology Nursing Society (EONS). Thisyear, it
CANCER CAUSED BY OCCUPATIONAL EXPOSURE NEEDS URGENT What is the cancer burden associated with occupational exposure? A new review shows that the question needs urgent attention, given under-reporting and current difficulties in estimating the global burden. The review, in Molecular Oncology, highlights how millions of workers are exposed daily to crystalline silica in mineral dust, diesel engine exhaust emissions, welding fumes and GORDON MCVIE 1945–2021: A LIFETIME DEDICATED TO DEFEATING Gordon McVie passed away on January 20th after a lifetime of pioneering contributions to the cause of defeating cancer: as clinician, researcher, manager, advocate and educator. He was a formidable presence on the UK and European stage, driven by a conviction that science can and will defeat cancer; quick to spot and embrace new opportunities; THE COST OF CANCER IN EUROPE Thomas Hofmarcher is a health economist with a strong focus on policy-relevant analysis. He is an expert of cost-of-illness analysis, patient access studies, cost-effectiveness analysis, budget impact analysis, market forecast models to the application of advanced econometric methods in both Swedish and European contexts. STUDY BRINGS MASS BIPARAMETRIC MRI SCREENING FOR PROSTATE Using biparametric (bp) magnetic resonance imaging (MRI) to screen for prostate cancer identified twice as many clinically significant cancers as standard prostate-specific antigen (PSA) tests. Moreover, the UK study, reported in JAMA Oncology (11 February), found bpMRI improved detection of prostate cancers without leading to unnecessary biopsy or over diagnosis. DOSE DENSE CHEMOTHERAPY IN LUMINAL B BREAST CANCERS A. The paper confirms that dose-dense chemotherapy is more efficacious compared to standard interval chemotherapy in high risk breast cancer patients like patients with Luminal B cancer. Dose-dense chemotherapy is associated with a 8% absolute increase in 8-year overall survival and a relative decrease of the risk of death of 39%. MANAGING COMMON TOXICITIES WITH NEW TYROSINE KINASESEE MORE ON ARCHIVE.CANCERWORLD.NET NUTRITIONAL SUPPORT FOR CANCER PATIENTS Patients who are receiving adequate nutrition have a better prognosis, respond better to chemotherapy and can tolerate higher doses of anticancer treatments. It is therefore important for oncologists to assess and manage malnutrition. Malnutrition, which is easily identified during clinical examination by weight loss and hypophagia, is an independent negative prognostic factor for cancer WHEN YOUR TIME IS UP. CONVERSATIONS ABOUT DYING FROM Kidney failure is another common cause of death, as the body’s metabolism goes down: “The patient starts with dehydration, and that leads to kidney failure and the patient dies from renal failure. Any possibility can happen in any kind of cancer.”. WHEN PATIENTS ASK YOU TO HELP THEM DIECANCER WORLD
Cancer Nurses – The Key To Prevention, Risk Reduction And Tackling The European Cancer Burden. External Contributor. 11 May 2021. European Cancer Nursing Day (ECND21), takes place every year on 18 May, organised by the European Oncology Nursing Society (EONS). Thisyear, it
CANCER CAUSED BY OCCUPATIONAL EXPOSURE NEEDS URGENT What is the cancer burden associated with occupational exposure? A new review shows that the question needs urgent attention, given under-reporting and current difficulties in estimating the global burden. The review, in Molecular Oncology, highlights how millions of workers are exposed daily to crystalline silica in mineral dust, diesel engine exhaust emissions, welding fumes and GORDON MCVIE 1945–2021: A LIFETIME DEDICATED TO DEFEATING Gordon McVie passed away on January 20th after a lifetime of pioneering contributions to the cause of defeating cancer: as clinician, researcher, manager, advocate and educator. He was a formidable presence on the UK and European stage, driven by a conviction that science can and will defeat cancer; quick to spot and embrace new opportunities; THE COST OF CANCER IN EUROPE Thomas Hofmarcher is a health economist with a strong focus on policy-relevant analysis. He is an expert of cost-of-illness analysis, patient access studies, cost-effectiveness analysis, budget impact analysis, market forecast models to the application of advanced econometric methods in both Swedish and European contexts. STUDY BRINGS MASS BIPARAMETRIC MRI SCREENING FOR PROSTATE Using biparametric (bp) magnetic resonance imaging (MRI) to screen for prostate cancer identified twice as many clinically significant cancers as standard prostate-specific antigen (PSA) tests. Moreover, the UK study, reported in JAMA Oncology (11 February), found bpMRI improved detection of prostate cancers without leading to unnecessary biopsy or over diagnosis. DOSE DENSE CHEMOTHERAPY IN LUMINAL B BREAST CANCERS A. The paper confirms that dose-dense chemotherapy is more efficacious compared to standard interval chemotherapy in high risk breast cancer patients like patients with Luminal B cancer. Dose-dense chemotherapy is associated with a 8% absolute increase in 8-year overall survival and a relative decrease of the risk of death of 39%. MANAGING COMMON TOXICITIES WITH NEW TYROSINE KINASESEE MORE ON ARCHIVE.CANCERWORLD.NET NUTRITIONAL SUPPORT FOR CANCER PATIENTS Patients who are receiving adequate nutrition have a better prognosis, respond better to chemotherapy and can tolerate higher doses of anticancer treatments. It is therefore important for oncologists to assess and manage malnutrition. Malnutrition, which is easily identified during clinical examination by weight loss and hypophagia, is an independent negative prognostic factor for cancer WHEN YOUR TIME IS UP. CONVERSATIONS ABOUT DYING FROM Kidney failure is another common cause of death, as the body’s metabolism goes down: “The patient starts with dehydration, and that leads to kidney failure and the patient dies from renal failure. Any possibility can happen in any kind of cancer.”. WHEN PATIENTS ASK YOU TO HELP THEM DIE WWW.CANCERWORLD.NET ISSUE 90 SUMMER 2021 Scan to access haping the future of cancer care our website Readership of over 000 ‘Covid did not stop cancer research’ by Vito Manolo Roma Editor-in-chief Adriana Albini Senior Associate Editor HIGHLIGHTS OF 2020 AMERICAN SOCIETY OF HEMATOLOGY (ASH Like most 2020 meetings the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held 5-8 December, was hosted virtually. Due to meticulous planning, the format did not prevent delegates attending the largest gathering of the professional haematology community from undergoing the full conference experience. There was a wide ranging and innovative scientific CONTAGION: A NARRATIVE APPROACH TO UNDERSTANDING THE The coronavirus pandemic, as experienced in the lives of individuals and by society, is so much more than a biological phenomenon. We need to grasp this to effectively address the continuing damage it is doingas we move forward.
DOSE DENSE CHEMOTHERAPY IN LUMINAL B BREAST CANCERS A. The paper confirms that dose-dense chemotherapy is more efficacious compared to standard interval chemotherapy in high risk breast cancer patients like patients with Luminal B cancer. Dose-dense chemotherapy is associated with a 8% absolute increase in 8-year overall survival and a relative decrease of the risk of death of 39%. HIGHLIGHTS OF 2020 SAN ANTONIO BREAST CANCER SYMPOSIUM In 2020, the San Antonio Breast Cancer Symposium (SABCS) co-organised in association with the American Association for Cancer Research (AACR) celebrated its 43rd year as the world’s premier annual breast oncology meeting. Like most conferences, due to the Covid-19 pandemic, for the first time this meeting was hosted as a virtual event. RARE CANCER CARE: ARE EUROPEAN REFERENCE NETWORKS The EURACAN network is split into 10 ‘domains’, which correspond to the 10 areas of expertise in of rare adult solid tumours. Paolo Casali, director of one of the medical oncology units at the Istituto Nazionale dei Tumori in Milan, leads the work in the sarcoma domain, and says the structure functions well enough. JOSÉ BASELGA: A GIANT OF MEDICAL ONCOLOGY José Baselga, one of the most high profile oncologists of recent times, has died at the age of 61. His fame in the cancer world is confirmed by the volume of tributes on social media and websites globally, and in particular from those in the US and the Catalonia region of Spain, his native country. SOLANGE PETERS: ESMO PRESIDENT The second woman ever to hold the ESMO presidency, Solange Peters brings to the role impressive clinical and research experience in lung cancer, one of the most challenging and fast-moving areas of oncology. Cancer World asked her about how ESMO is adapting to meet the needs of oncologists in today’s complex and rapidly changing clinicalREFUSING TREATMENT
Although the refusal of cancer treatment is a serious concern and has been shown to reduce the effectiveness of treatment and decrease survival duration after diagnosis , the phenomenon itself has been scarcely studied. The number of patients who make this decision is not very well known, but the number appears substantial enough to HOW DOCTORS DIE. IT’S NOT LIKE THE REST OF US, BUT IT This hard-hitting blogpost by Ken Murray, a retired Los Angeles family doctor, helped open up discussions about why doctors routinely administer treatments to dying patients that they would adamantly refuse for themselves. Years ago, Charlie, a highly respected orthopaedist and a mentor of mine, found a lump in his stomach. He hada surgeon explore
CANCER WORLD
Cancer Nurses – The Key To Prevention, Risk Reduction And Tackling The European Cancer Burden. External Contributor. 11 May 2021. European Cancer Nursing Day (ECND21), takes place every year on 18 May, organised by the European Oncology Nursing Society (EONS). Thisyear, it
CANCER CAUSED BY OCCUPATIONAL EXPOSURE NEEDS URGENT What is the cancer burden associated with occupational exposure? A new review shows that the question needs urgent attention, given under-reporting and current difficulties in estimating the global burden. The review, in Molecular Oncology, highlights how millions of workers are exposed daily to crystalline silica in mineral dust, diesel engine exhaust emissions, welding fumes and GORDON MCVIE 1945–2021: A LIFETIME DEDICATED TO DEFEATING Gordon McVie passed away on January 20th after a lifetime of pioneering contributions to the cause of defeating cancer: as clinician, researcher, manager, advocate and educator. He was a formidable presence on the UK and European stage, driven by a conviction that science can and will defeat cancer; quick to spot and embrace new opportunities; HIGHLIGHTS OF 2020 SAN ANTONIO BREAST CANCER SYMPOSIUM In 2020, the San Antonio Breast Cancer Symposium (SABCS) co-organised in association with the American Association for Cancer Research (AACR) celebrated its 43rd year as the world’s premier annual breast oncology meeting. Like most conferences, due to the Covid-19 pandemic, for the first time this meeting was hosted as a virtual event. THE COST OF CANCER IN EUROPE Thomas Hofmarcher is a health economist with a strong focus on policy-relevant analysis. He is an expert of cost-of-illness analysis, patient access studies, cost-effectiveness analysis, budget impact analysis, market forecast models to the application of advanced econometric methods in both Swedish and European contexts. STUDY BRINGS MASS BIPARAMETRIC MRI SCREENING FOR PROSTATE Using biparametric (bp) magnetic resonance imaging (MRI) to screen for prostate cancer identified twice as many clinically significant cancers as standard prostate-specific antigen (PSA) tests. Moreover, the UK study, reported in JAMA Oncology (11 February), found bpMRI improved detection of prostate cancers without leading to unnecessary biopsy or over diagnosis. DOSE DENSE CHEMOTHERAPY IN LUMINAL B BREAST CANCERS A. The paper confirms that dose-dense chemotherapy is more efficacious compared to standard interval chemotherapy in high risk breast cancer patients like patients with Luminal B cancer. Dose-dense chemotherapy is associated with a 8% absolute increase in 8-year overall survival and a relative decrease of the risk of death of 39%. MANAGING COMMON TOXICITIES WITH NEW TYROSINE KINASESEE MORE ON ARCHIVE.CANCERWORLD.NET WHEN YOUR TIME IS UP. CONVERSATIONS ABOUT DYING FROM Kidney failure is another common cause of death, as the body’s metabolism goes down: “The patient starts with dehydration, and that leads to kidney failure and the patient dies from renal failure. Any possibility can happen in any kind of cancer.”. WHEN PATIENTS ASK YOU TO HELP THEM DIECANCER WORLD
Cancer Nurses – The Key To Prevention, Risk Reduction And Tackling The European Cancer Burden. External Contributor. 11 May 2021. European Cancer Nursing Day (ECND21), takes place every year on 18 May, organised by the European Oncology Nursing Society (EONS). Thisyear, it
CANCER CAUSED BY OCCUPATIONAL EXPOSURE NEEDS URGENT What is the cancer burden associated with occupational exposure? A new review shows that the question needs urgent attention, given under-reporting and current difficulties in estimating the global burden. The review, in Molecular Oncology, highlights how millions of workers are exposed daily to crystalline silica in mineral dust, diesel engine exhaust emissions, welding fumes and GORDON MCVIE 1945–2021: A LIFETIME DEDICATED TO DEFEATING Gordon McVie passed away on January 20th after a lifetime of pioneering contributions to the cause of defeating cancer: as clinician, researcher, manager, advocate and educator. He was a formidable presence on the UK and European stage, driven by a conviction that science can and will defeat cancer; quick to spot and embrace new opportunities; THE COST OF CANCER IN EUROPE Thomas Hofmarcher is a health economist with a strong focus on policy-relevant analysis. He is an expert of cost-of-illness analysis, patient access studies, cost-effectiveness analysis, budget impact analysis, market forecast models to the application of advanced econometric methods in both Swedish and European contexts. STUDY BRINGS MASS BIPARAMETRIC MRI SCREENING FOR PROSTATE Using biparametric (bp) magnetic resonance imaging (MRI) to screen for prostate cancer identified twice as many clinically significant cancers as standard prostate-specific antigen (PSA) tests. Moreover, the UK study, reported in JAMA Oncology (11 February), found bpMRI improved detection of prostate cancers without leading to unnecessary biopsy or over diagnosis. DOSE DENSE CHEMOTHERAPY IN LUMINAL B BREAST CANCERS A. The paper confirms that dose-dense chemotherapy is more efficacious compared to standard interval chemotherapy in high risk breast cancer patients like patients with Luminal B cancer. Dose-dense chemotherapy is associated with a 8% absolute increase in 8-year overall survival and a relative decrease of the risk of death of 39%. MANAGING COMMON TOXICITIES WITH NEW TYROSINE KINASESEE MORE ON ARCHIVE.CANCERWORLD.NET WHEN YOUR TIME IS UP. CONVERSATIONS ABOUT DYING FROM Kidney failure is another common cause of death, as the body’s metabolism goes down: “The patient starts with dehydration, and that leads to kidney failure and the patient dies from renal failure. Any possibility can happen in any kind of cancer.”. WHEN PATIENTS ASK YOU TO HELP THEM DIE HOW DOCTORS DIE. IT’S NOT LIKE THE REST OF US, BUT IT This hard-hitting blogpost by Ken Murray, a retired Los Angeles family doctor, helped open up discussions about why doctors routinely administer treatments to dying patients that they would adamantly refuse for themselves. Years ago, Charlie, a highly respected orthopaedist and a mentor of mine, found a lump in his stomach. He hada surgeon explore
OBITUARIES | CANCER WORLD MAGAZINE Obituaries. Gordon McVie 1945–2021: a lifetime dedicated to defeating cancer. Adriana Albini. 22 January 2021. Gordon McVie passed away on January 20th after a lifetime of pioneering contributions to the cause of defeating cancer: as clinician, researcher, manager, advocate and educator. He was a formidable. HIGHLIGHTS OF 2020 SAN ANTONIO BREAST CANCER SYMPOSIUM In 2020, the San Antonio Breast Cancer Symposium (SABCS) co-organised in association with the American Association for Cancer Research (AACR) celebrated its 43rd year as the world’s premier annual breast oncology meeting. Like most conferences, due to the Covid-19 pandemic, for the first time this meeting was hosted as a virtual event. HIGHLIGHTS OF 2020 AMERICAN SOCIETY OF HEMATOLOGY (ASH Like most 2020 meetings the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held 5-8 December, was hosted virtually. Due to meticulous planning, the format did not prevent delegates attending the largest gathering of the professional haematology community from undergoing the full conference experience. There was a wide ranging and innovative scientific JOSÉ BASELGA: A GIANT OF MEDICAL ONCOLOGY José Baselga, one of the most high profile oncologists of recent times, has died at the age of 61. His fame in the cancer world is confirmed by the volume of tributes on social media and websites globally, and in particular from those in the US and the Catalonia region of Spain, his native country. RARE CANCER CARE: ARE EUROPEAN REFERENCE NETWORKS The EURACAN network is split into 10 ‘domains’, which correspond to the 10 areas of expertise in of rare adult solid tumours. Paolo Casali, director of one of the medical oncology units at the Istituto Nazionale dei Tumori in Milan, leads the work in the sarcoma domain, and says the structure functions well enough. SOLANGE PETERS: ESMO PRESIDENT The second woman ever to hold the ESMO presidency, Solange Peters brings to the role impressive clinical and research experience in lung cancer, one of the most challenging and fast-moving areas of oncology. Cancer World asked her about how ESMO is adapting to meet the needs of oncologists in today’s complex and rapidly changing clinical EASING THE CANCER JOURNEY It found that 77% of childhood cancer patients do not live in a city with a principal treatment centre and that the average round trip travelled for treatment by children and their families is 60 miles, taking on average one hour 50 minutes. But some children and their families reported a round-trip of 902 miles, taking 16 hours.REFUSING TREATMENT
Studies have reported rates of less than 1% for patients who refused all conventional treatment and 3–19% for patients who refused chemotherapy partially or completely . We tend to think that refusing therapy leads to a poorer quality of life as the disease progresses without treatment. HOW DOCTORS DIE. IT’S NOT LIKE THE REST OF US, BUT IT This hard-hitting blogpost by Ken Murray, a retired Los Angeles family doctor, helped open up discussions about why doctors routinely administer treatments to dying patients that they would adamantly refuse for themselves. Years ago, Charlie, a highly respected orthopaedist and a mentor of mine, found a lump in his stomach. He hada surgeon explore
IS THIS THE END FOR THE MICROSCOPE? Implementing major change to complex procedures rarely goes smoothly, particularly when IT systems are involved. Capitanio, in Sweden, says the main problem in his lab was the transition from the microscope to the computer for the pathologists. “Some simply don’t want to doit.”.
CANCER WORLD
Cancer Nurses – The Key To Prevention, Risk Reduction And Tackling The European Cancer Burden. External Contributor. 11 May 2021. European Cancer Nursing Day (ECND21), takes place every year on 18 May, organised by the European Oncology Nursing Society (EONS). Thisyear, it
CANCER CAUSED BY OCCUPATIONAL EXPOSURE NEEDS URGENT What is the cancer burden associated with occupational exposure? A new review shows that the question needs urgent attention, given under-reporting and current difficulties in estimating the global burden. The review, in Molecular Oncology, highlights how millions of workers are exposed daily to crystalline silica in mineral dust, diesel engine exhaust emissions, welding fumes and GORDON MCVIE 1945–2021: A LIFETIME DEDICATED TO DEFEATING Gordon McVie passed away on January 20th after a lifetime of pioneering contributions to the cause of defeating cancer: as clinician, researcher, manager, advocate and educator. He was a formidable presence on the UK and European stage, driven by a conviction that science can and will defeat cancer; quick to spot and embrace new opportunities; HIGHLIGHTS OF 2020 SAN ANTONIO BREAST CANCER SYMPOSIUM In 2020, the San Antonio Breast Cancer Symposium (SABCS) co-organised in association with the American Association for Cancer Research (AACR) celebrated its 43rd year as the world’s premier annual breast oncology meeting. Like most conferences, due to the Covid-19 pandemic, for the first time this meeting was hosted as a virtual event. THE COST OF CANCER IN EUROPE Thomas Hofmarcher is a health economist with a strong focus on policy-relevant analysis. He is an expert of cost-of-illness analysis, patient access studies, cost-effectiveness analysis, budget impact analysis, market forecast models to the application of advanced econometric methods in both Swedish and European contexts. STUDY BRINGS MASS BIPARAMETRIC MRI SCREENING FOR PROSTATE Using biparametric (bp) magnetic resonance imaging (MRI) to screen for prostate cancer identified twice as many clinically significant cancers as standard prostate-specific antigen (PSA) tests. Moreover, the UK study, reported in JAMA Oncology (11 February), found bpMRI improved detection of prostate cancers without leading to unnecessary biopsy or over diagnosis. DOSE DENSE CHEMOTHERAPY IN LUMINAL B BREAST CANCERS A. The paper confirms that dose-dense chemotherapy is more efficacious compared to standard interval chemotherapy in high risk breast cancer patients like patients with Luminal B cancer. Dose-dense chemotherapy is associated with a 8% absolute increase in 8-year overall survival and a relative decrease of the risk of death of 39%. MANAGING COMMON TOXICITIES WITH NEW TYROSINE KINASESEE MORE ON ARCHIVE.CANCERWORLD.NET WHEN YOUR TIME IS UP. CONVERSATIONS ABOUT DYING FROM Kidney failure is another common cause of death, as the body’s metabolism goes down: “The patient starts with dehydration, and that leads to kidney failure and the patient dies from renal failure. Any possibility can happen in any kind of cancer.”. WHEN PATIENTS ASK YOU TO HELP THEM DIECANCER WORLD
Cancer Nurses – The Key To Prevention, Risk Reduction And Tackling The European Cancer Burden. External Contributor. 11 May 2021. European Cancer Nursing Day (ECND21), takes place every year on 18 May, organised by the European Oncology Nursing Society (EONS). Thisyear, it
CANCER CAUSED BY OCCUPATIONAL EXPOSURE NEEDS URGENT What is the cancer burden associated with occupational exposure? A new review shows that the question needs urgent attention, given under-reporting and current difficulties in estimating the global burden. The review, in Molecular Oncology, highlights how millions of workers are exposed daily to crystalline silica in mineral dust, diesel engine exhaust emissions, welding fumes and GORDON MCVIE 1945–2021: A LIFETIME DEDICATED TO DEFEATING Gordon McVie passed away on January 20th after a lifetime of pioneering contributions to the cause of defeating cancer: as clinician, researcher, manager, advocate and educator. He was a formidable presence on the UK and European stage, driven by a conviction that science can and will defeat cancer; quick to spot and embrace new opportunities; HIGHLIGHTS OF 2020 SAN ANTONIO BREAST CANCER SYMPOSIUM In 2020, the San Antonio Breast Cancer Symposium (SABCS) co-organised in association with the American Association for Cancer Research (AACR) celebrated its 43rd year as the world’s premier annual breast oncology meeting. Like most conferences, due to the Covid-19 pandemic, for the first time this meeting was hosted as a virtual event. THE COST OF CANCER IN EUROPE Thomas Hofmarcher is a health economist with a strong focus on policy-relevant analysis. He is an expert of cost-of-illness analysis, patient access studies, cost-effectiveness analysis, budget impact analysis, market forecast models to the application of advanced econometric methods in both Swedish and European contexts. STUDY BRINGS MASS BIPARAMETRIC MRI SCREENING FOR PROSTATE Using biparametric (bp) magnetic resonance imaging (MRI) to screen for prostate cancer identified twice as many clinically significant cancers as standard prostate-specific antigen (PSA) tests. Moreover, the UK study, reported in JAMA Oncology (11 February), found bpMRI improved detection of prostate cancers without leading to unnecessary biopsy or over diagnosis. DOSE DENSE CHEMOTHERAPY IN LUMINAL B BREAST CANCERS A. The paper confirms that dose-dense chemotherapy is more efficacious compared to standard interval chemotherapy in high risk breast cancer patients like patients with Luminal B cancer. Dose-dense chemotherapy is associated with a 8% absolute increase in 8-year overall survival and a relative decrease of the risk of death of 39%. MANAGING COMMON TOXICITIES WITH NEW TYROSINE KINASESEE MORE ON ARCHIVE.CANCERWORLD.NET WHEN YOUR TIME IS UP. CONVERSATIONS ABOUT DYING FROM Kidney failure is another common cause of death, as the body’s metabolism goes down: “The patient starts with dehydration, and that leads to kidney failure and the patient dies from renal failure. Any possibility can happen in any kind of cancer.”. WHEN PATIENTS ASK YOU TO HELP THEM DIE OBITUARIES | CANCER WORLD MAGAZINE Obituaries. Gordon McVie 1945–2021: a lifetime dedicated to defeating cancer. Adriana Albini. 22 January 2021. Gordon McVie passed away on January 20th after a lifetime of pioneering contributions to the cause of defeating cancer: as clinician, researcher, manager, advocate and educator. He was a formidable. HIGHLIGHTS OF 2020 SAN ANTONIO BREAST CANCER SYMPOSIUM In 2020, the San Antonio Breast Cancer Symposium (SABCS) co-organised in association with the American Association for Cancer Research (AACR) celebrated its 43rd year as the world’s premier annual breast oncology meeting. Like most conferences, due to the Covid-19 pandemic, for the first time this meeting was hosted as a virtual event. HIGHLIGHTS OF 2020 AMERICAN SOCIETY OF HEMATOLOGY (ASH Like most 2020 meetings the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, held 5-8 December, was hosted virtually. Due to meticulous planning, the format did not prevent delegates attending the largest gathering of the professional haematology community from undergoing the full conference experience. There was a wide ranging and innovative scientific JOSÉ BASELGA: A GIANT OF MEDICAL ONCOLOGY José Baselga, one of the most high profile oncologists of recent times, has died at the age of 61. His fame in the cancer world is confirmed by the volume of tributes on social media and websites globally, and in particular from those in the US and the Catalonia region of Spain, his native country. RARE CANCER CARE: ARE EUROPEAN REFERENCE NETWORKS The EURACAN network is split into 10 ‘domains’, which correspond to the 10 areas of expertise in of rare adult solid tumours. Paolo Casali, director of one of the medical oncology units at the Istituto Nazionale dei Tumori in Milan, leads the work in the sarcoma domain, and says the structure functions well enough. SOLANGE PETERS: ESMO PRESIDENT The second woman ever to hold the ESMO presidency, Solange Peters brings to the role impressive clinical and research experience in lung cancer, one of the most challenging and fast-moving areas of oncology. Cancer World asked her about how ESMO is adapting to meet the needs of oncologists in today’s complex and rapidly changing clinical EASING THE CANCER JOURNEY It found that 77% of childhood cancer patients do not live in a city with a principal treatment centre and that the average round trip travelled for treatment by children and their families is 60 miles, taking on average one hour 50 minutes. But some children and their families reported a round-trip of 902 miles, taking 16 hours.REFUSING TREATMENT
Studies have reported rates of less than 1% for patients who refused all conventional treatment and 3–19% for patients who refused chemotherapy partially or completely . We tend to think that refusing therapy leads to a poorer quality of life as the disease progresses without treatment. HOW DOCTORS DIE. IT’S NOT LIKE THE REST OF US, BUT IT This hard-hitting blogpost by Ken Murray, a retired Los Angeles family doctor, helped open up discussions about why doctors routinely administer treatments to dying patients that they would adamantly refuse for themselves. Years ago, Charlie, a highly respected orthopaedist and a mentor of mine, found a lump in his stomach. He hada surgeon explore
IS THIS THE END FOR THE MICROSCOPE? Implementing major change to complex procedures rarely goes smoothly, particularly when IT systems are involved. Capitanio, in Sweden, says the main problem in his lab was the transition from the microscope to the computer for the pathologists. “Some simply don’t want to doit.”.
CANCER WORLD
Cancer World explores cancer care from all viewpoints publishing online articles and news weekly and a print version twice a year. CANCER CAUSED BY OCCUPATIONAL EXPOSURE NEEDS URGENT What is the cancer burden associated with occupational exposure? A new review shows that the question needs urgent attention, given under-reporting and current difficulties in estimating the global burden. The review, in Molecular Oncology, highlights how millions of workers are exposed daily to crystalline silica in mineral dust, diesel engine exhaust emissions, welding fumes and GORDON MCVIE 1945–2021: A LIFETIME DEDICATED TO DEFEATING Gordon McVie passed away on January 20th after a lifetime of pioneering contributions to the cause of defeating cancer: as clinician, researcher, manager, advocate and educator. He was a formidable presence on the UK and European stage, driven by a conviction that science can and will defeat cancer; quick to spot and embrace new opportunities; WHEN YOUR TIME IS UP. CONVERSATIONS ABOUT DYING FROM Cancer has traditionally been the diagnosis people fear most. But is dying from cancer so much worse than the alternatives? Anna Wagstaff tries to make sense of an emotive discussion that all started with a post on the BMJ blog. “How do you want to die? You must think aboutit.” This is
MANAGING COMMON TOXICITIES WITH NEW TYROSINE KINASESEE MORE ON ARCHIVE.CANCERWORLD.NET HOW TO FILL THE GENDER GAP IN ONCOLOGY The lack of women in apical positions is a weakness of oncology, and a loss for patients. Mentorship programs launched in recent years by scientific societies like ESMO and ASCO, together with practical support for career development, are starting to address the many factors that make the climb to success steeper for women The 2018 WHEN PATIENTS ASK YOU TO HELP THEM DIE IS THIS THE END FOR THE MICROSCOPE? New generations of precision digital scanners are threatening to replace the tool that has been the iconic symbol of pathology for so long. Maria Delaney reports. Glass slides containing tissues and cells are sitting in piles on a shelf in the pathology lab. They wait here until the consultant picks up a stack and carries RECOGNISING AND REDUCING THE RISK OF CHEMOTHERAPYSEE MORE ON ARCHIVE.CANCERWORLD.NET HOW DOCTORS DIE. IT’S NOT LIKE THE REST OF US, BUT ITREVIEW THE REST OF USTHE REST OF US BOOKTHE REST OF US RATINGTHE REST OF US SOUNDTRACKTHE REST OF US TRAILERDIES R US DIES This hard-hitting blogpost by Ken Murray, a retired Los Angeles family doctor, helped open up discussions about why doctors routinely administer treatments to dying patients that they would adamantly refuse for themselves. Years ago, Charlie, a highly respected orthopaedist and a mentor of mine, found a lump in his stomach. He hada surgeon explore
CANCER WORLD
Cancer World explores cancer care from all viewpoints publishing online articles and news weekly and a print version twice a year. CANCER CAUSED BY OCCUPATIONAL EXPOSURE NEEDS URGENT What is the cancer burden associated with occupational exposure? A new review shows that the question needs urgent attention, given under-reporting and current difficulties in estimating the global burden. The review, in Molecular Oncology, highlights how millions of workers are exposed daily to crystalline silica in mineral dust, diesel engine exhaust emissions, welding fumes and GORDON MCVIE 1945–2021: A LIFETIME DEDICATED TO DEFEATING Gordon McVie passed away on January 20th after a lifetime of pioneering contributions to the cause of defeating cancer: as clinician, researcher, manager, advocate and educator. He was a formidable presence on the UK and European stage, driven by a conviction that science can and will defeat cancer; quick to spot and embrace new opportunities; WHEN YOUR TIME IS UP. CONVERSATIONS ABOUT DYING FROM Cancer has traditionally been the diagnosis people fear most. But is dying from cancer so much worse than the alternatives? Anna Wagstaff tries to make sense of an emotive discussion that all started with a post on the BMJ blog. “How do you want to die? You must think aboutit.” This is
MANAGING COMMON TOXICITIES WITH NEW TYROSINE KINASESEE MORE ON ARCHIVE.CANCERWORLD.NET HOW TO FILL THE GENDER GAP IN ONCOLOGY The lack of women in apical positions is a weakness of oncology, and a loss for patients. Mentorship programs launched in recent years by scientific societies like ESMO and ASCO, together with practical support for career development, are starting to address the many factors that make the climb to success steeper for women The 2018 WHEN PATIENTS ASK YOU TO HELP THEM DIE IS THIS THE END FOR THE MICROSCOPE? New generations of precision digital scanners are threatening to replace the tool that has been the iconic symbol of pathology for so long. Maria Delaney reports. Glass slides containing tissues and cells are sitting in piles on a shelf in the pathology lab. They wait here until the consultant picks up a stack and carries RECOGNISING AND REDUCING THE RISK OF CHEMOTHERAPYSEE MORE ON ARCHIVE.CANCERWORLD.NET HOW DOCTORS DIE. IT’S NOT LIKE THE REST OF US, BUT ITREVIEW THE REST OF USTHE REST OF US BOOKTHE REST OF US RATINGTHE REST OF US SOUNDTRACKTHE REST OF US TRAILERDIES R US DIES This hard-hitting blogpost by Ken Murray, a retired Los Angeles family doctor, helped open up discussions about why doctors routinely administer treatments to dying patients that they would adamantly refuse for themselves. Years ago, Charlie, a highly respected orthopaedist and a mentor of mine, found a lump in his stomach. He hada surgeon explore
CANCER CAUSED BY OCCUPATIONAL EXPOSURE NEEDS URGENT What is the cancer burden associated with occupational exposure? A new review shows that the question needs urgent attention, given under-reporting and current difficulties in estimating the global burden. The review, in Molecular Oncology, highlights how millions of workers are exposed daily to crystalline silica in mineral dust, diesel engine exhaust emissions, welding fumes and RETURNING TO ‘NORMAL’ AND BEATING CANCER IN EUROPE 2021 An ageing population, environmental factors, infectious agents, and lifestyle changes all add to the rising impact of cancer on our lives. If nothing is done, cancer will soon become the leading cause of death in Europe. A comprehensive collaboration across all sectors could reverse this rapidly rising trend. Up to four in ten cases of TRUST ME: I’M A SURGICAL ONCOLOGIST! Cancer patients need confidence that their surgeon understands cancer and all treatment options, as well as having technical expertise in the often complex procedure they will be performing. WAKE-UP CALL TO OFFER EQUAL ACCESS TO LIFE-PROLONGING Less than one third of men with metastatic castration-sensitive prostate cancer (mCSPC) received established treatment intensification by 2018 that had been demonstrated to extend survival. The US study evaluating real-world utilization of advanced therapies, abstract 5073, released in advance of the forthcoming ASCO meeting, taking place online June 4-8, furthermore revealed concerning data RARE CANCER CARE: ARE EUROPEAN REFERENCE NETWORKS What value can collaboration between EU member states add to the quality of care accessible to all EU citizens? It’s a question that has become urgent and topical with the coronavirus pandemic, and one that EU4Health, the EU’s new funding programme “for a healthier and safer Union”, presented at the end of May, seeks to address.Part of the programme involves expanding existing JOSÉ BASELGA: A GIANT OF MEDICAL ONCOLOGY José Baselga, one of the most high profile oncologists of recent times, has died at the age of 61. His fame in the cancer world is confirmed by the volume of tributes on social media and websites globally, and in particular from those in the US and the Catalonia region of Spain, his native country. STUDY BRINGS MASS BIPARAMETRIC MRI SCREENING FOR PROSTATE Using biparametric (bp) magnetic resonance imaging (MRI) to screen for prostate cancer identified twice as many clinically significant cancers as standard prostate-specific antigen (PSA) tests. Moreover, the UK study, reported in JAMA Oncology (11 February), found bpMRI improved detection of prostate cancers without leading to unnecessary biopsy or over diagnosis. IN MEMORY OF ARON GOLDHIRSCH, CHALLENGING ONCOLOGIST WITH Prof. Aron Goldhirsch, an outstanding representative of italian Medical Oncology, awarded and recognized internationally, passed away on February 26. Since 2019, he was Medical Consultant at the Breast Cancer Center in Multimedica (Milan, Italy). For many years he held the position of Senior Consultant for the Senology Program and Director of the Melanoma, Sarcoma and RECOGNISING AND REDUCING THE RISK OF CHEMOTHERAPY When chemotherapy drugs leak from the veins it can cause serious injury to the patient, greatly heighten their fears of undergoing future treatment cycles, and undermine their trust in their medical team. Knowing how to assess and reduce the risks, and what to do when things go wrong, is essential. Extravasation occurs when medicinesleak
THE COST OF CANCER IN EUROPE Thomas Hofmarcher is a health economist with a strong focus on policy-relevant analysis. He is an expert of cost-of-illness analysis, patient access studies, cost-effectiveness analysis, budget impact analysis, market forecast models to the application of advanced econometric methods in both Swedish and European contexts.MENU
* Home
* News
* Magazine
* Media Partnership
* About us
* Contacts
* __Facebook
* __Twitter
* Home
* News
* Magazine
* Media Partnership
* About us
* Contacts
Search for:
*
HOW TO MAKE PRECISION DRUGS THAT WORK BETTER Six lessons from the development of the first targeted anti-cancer therapy Why are today’s precision drugs falling so short of the impact achieved by tamoxifen, the first ever targeted cancer therapy? Craig Jordan puts it*
WOMEN MAKE GREAT SURGEONS, SO WHY IS THE PROFESSION STILL DOMINATEDBY MEN?
Once seen as an exclusive ‘men’s club’, women have broken into the surgical profession over the past 50 years and proved their value. Yet they remain significantly underrepresented, particularly at the higher echelons, even in*
EVIDENCE-BASED MEDICINE AND PRECISION MEDICINE – IRRECONCILABLE ORINSEPARABLE?
How do you build an evidence base to inform treatment choices that are tailored to the unique genomic profile of each patient and their disease? Sophie Fessl talks to some leading clinical researchers andstatisticians
*
HOW RETRACTIONS ARE HELPING CANCER RESEARCH Retraction Watch was born as a blog to unveil the reasons behind the retraction of a paper. It is now a comprehensive database helping to foster a better quality of research, including in oncology. Esther*
RIGHT DRUG, WRONG PATIENT: HERE’S HOW WE IMPROVE OUR TARGETING Most of the revolutionary techniques now used to investigate cancers, their development and response to treatments were already ‘old news’ by the time Balkees Abderrahman entered cancer research. Currently a Living Legend Fellow of Cancer*
HOW TO MAKE PRECISION DRUGS THAT WORK BETTER Six lessons from the development of the first targeted anti-cancer therapy Why are today’s precision drugs falling so short of the impact achieved by tamoxifen, the first ever targeted cancer therapy? Craig Jordan puts it*
WOMEN MAKE GREAT SURGEONS, SO WHY IS THE PROFESSION STILL DOMINATEDBY MEN?
Once seen as an exclusive ‘men’s club’, women have broken into the surgical profession over the past 50 years and proved their value. Yet they remain significantly underrepresented, particularly at the higher echelons, even in* 1
* 2
* 3
* 4
* 5
LATEST NEWS
*
CANCER SURVIVORS NEED MORE (AND LONGER) SUPPORT __News __23 March 2020 __0 After defeating cancer, people are facing other worries, which too often remain unsolved, even though they are seeking for help, according to a Canadian study concluding that it’s*
COVID-19: ECCO DEMANDS ATTENTION TO PROTECT CANCER PATIENTS __News __17 March 2020 __0 The COVID-19 pandemic poses a significant threat for cancer patients, which deserve to be protected through immediate action on several levels all over Europe, according to a statementSUBSCRIBE NOW
*
LATEST PRINTED ISSUEWE SUPPORT
*
VOICES
*
COVID – ARE CANCER PATIENTS BEING PROTECTED? __voices __18 March 2020__0
This is a particularly worrying time for people going through chemotherapy and other treatments that suppress the immune system. So what advice is being offeredSUBSCRIBE NOW
*
*
*
*
*
Copyright ESO 2018 with all rights reserved - Credits -__ UA-77507851-1
×
Notice
This website or its third-party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the cookie policy.
By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies.Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0